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Human serum paraoxonase1 (HuPON1) belongs to the family of A-esterases (EC.3.1.8.1). It is associated with HDL particle and 
prevents atherosclerosis by cleaving lipid hydroperoxides and other proatherogenic molecules of oxidized low density lipoproteins 
(LDL). Since the precise structure of HuPON1 is not yet available, the structure-function relationship between HuPON1 and 
activators/inhibitors is still unknown. Therefore, a theoretical model of HuPON1 was generated using homology modelling and 
precise molecular interactions of an activator aspirin and an inhibitor cefazolin with PON1 were studied using Autodock software. 
The ligand binding residues were found to be similar to the predicted active site residues. Both cefazolin and aspirin were found to 
dock in the vicinity of the predicted active sites of PON1; cefazolin bound at residues N166, S193 and Y71, while aspirin at residues 
N309, I310 and L311. Binding region in the PON1 by prediction (3D2GO server) and docking studies provide useful insight into 
mechanism of substrate and inhibitor binding to the enzyme active site. 
 






Paraoxonase (EC 3.1.8.1) belongs to the family of A-esterases 
consisting of three members namely PON1, PON2 and PON3. 
PON1 and PON3 are produced in liver and secreted into blood. 
PON2 is not present in blood, but is expressed in tissues like 
liver, kidney, intestine, brain and heart. The genes coding for 
these enzymes are located adjacent to each other on the long 
arm of chromosome 7 (7q21.3-q22.1) [1]. PON1 is the most 
abundant form and hence extensively investigated. HuPON1 
consists of 355 amino acids exclusively associated with high-
density lipoprotein (HDL) in association with human 
phosphate binding protein (HPBP). ApoA1 is major protein in 
HDL which stabilizes PON1 and binds it with very high affinity 
[2]. HuPON1 plays a major role in the prevention of 
atherosclerosis by protecting HDL and LDL against oxidative 
stress mediated through the uptake of oxidized-LDL by 
macrophages, inhibition of macrophage cholesterol biosynthesis 
and stimulation of HDL mediated cholesterol efflux from 
macrophages  [3]. HuPON1 activity is reduced in type 1 and 
type 2 diabetes independent of individual’s genotype; hence 
diabetic patients are at high risk to develop atherosclerosis [4, 
5]. The low serum paraoxonase activity in type 2 diabetes was 
recently shown to be correlated with the levels of oxidized LDL 
and vascular complications [6]. A study demonstrated that 
HDL from type 1 diabetic patients showed higher levels of lipid 
hydroperoxides and lower activity of HDL-PON1 than healthy BIOINFORMATION  open access 
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subjects. Moreover, HDL from these patients was unable to 
protect erythrocyte membranes against oxidative damage. In 
diabetic patients, significant decrease in HuPON1 activity in the 
lipoprotein deficient serum (LPDS) fraction in comparison with 
healthy subjects was reported, where most of HuPON1 activity 
was in HDL [7]. The interest in HuPON1 is mainly because of 
its implications in cardiovascular diseases. HuPON1 being an 
antioxidant enzyme, also has a thiolactonase activity and 
prevents homocysteinylation of proteins by homocystein 
thiolactone  [8].  I t  c a n  a l s o  a c t i v a t e  s t a t i n  p r o d r u g s ,  m a n y  o f  
which are lactones. Hence, the cardioprotective functions of 
HDL are attributed to the HDL associated PON1.  Because of its 
great biological diversity, the active site of paraoxonase has 
received much attention from researchers for understanding the 
active site conformation capable of handling multiple 
substrates. Site directed mutagenesis and kinetics have 
identified various amino acids necessary for the different 
substrate binding and catalysis [9]. Since crystal structure of 
HuPON1 was not available, it has been modeled using crystal 
structure of rePON1 (rabbit PON1, PDB ID: 1V04). 
 
Aspirin is analgesic, anti-inflammatory and anti-pyretic drug, 
well known for treatment of cardiovascular diseases. A recent 
study reported in vitro and in vivo induction of PON1 and 
ApoA1 gene by aspirin and salicylate [10]. Studies have also 
shown aspirin competes with ρ-nitrophenylacetate and 
paraoxon for hydrolysis by PON1 in human plasma and 
isolated HDL preparations [11]. It also inhibits cyclooxygenase 
(COX) enzyme by acetylation of the active site and prevents the 
formation of cyclooxygenase products like prostaglandins, 
thromboxanes and prostacyclin [12]. Cefazolin sodium is a 
known cephalosporin antibiotic to inhibit Enterobacter aerogenes, 
Escherichia coli,  Haemophilus influenza,  Klebsiella species,  Proteus 
mirabilis and Streptococcus pneumonia. Cefazolin sodium 
significantly decreases liver glucose 6- phosphate 
dehydrogenase and human carbonic anhydrase I and II. A 
study has shown that cefazolin sodium causes a dose and time 
dependent decrease on PON1 activity in HepG2 cells and 
effectively inhibit purified human serum PON1 [13]. Though 
studies involving the effect of aspirin as an activator and 
cefazolin as an inhibitor of rePON1 have been reported [10, 13], 
no reports are available on the 3D model of HuPON1 with 
aspirin and cefazolin. In view of the above, the present study 
establishes the active site amino acid residues by in silico 
approaches and docking studies and also deduces the structural 




Sequence alignment and Structure prediction: 
The FASTA sequence of query protein (HuPON1) was retrieved 
from NCBI Entrez sequence search 
(http://www.ncbi.nlm.nih.gov). Following BLASTp run 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi), a Serum paraoxonase 
by directed evolution (PDB ID: 1V04) was selected as template 
sequence (http://www.rcsb.org/pdb). The sequences were 
subjected to pairwise alignment using ClustalW followed by 
secondary structure prediction using ESPript2.2 
(http://espript.ibcp.fr/ESPript). The 3D-structure of query 
protein was predicted by automated homology modeling 
program, Modeller9v8 [14]. For Modeller, the template and 
query sequences were carefully aligned to remove potential 
alignment errors. The default modeling process did end up 
with a loop. The model obtained was further submitted to 
modbase server 
(http://modbase.compbio.ucsf.edu/modloop/server) to 
rebuild the loop (Met1-Phe17) into its secondary structure. 
Validation of the model was done by Ramachandran plot 
analysis  [15]. Structural models were visualized by PyMol™ 
Molecular Graphics System version 0.97 
(http://www.pymol.org). 
 
Docking studies and Binding site prediction:  
Two molecules, aspirin (activator) and cefazolin (inhibitor) 
were chosen for docking studies. Docking study was carried out 
using Autodock software, which uses Genetic algorithm (GA). 
HuPON1 was loaded into AutoDock Tools (ADT) 
(http://autodock.scripps.edu/ resources) as a receptor and 
made ready for docking by the addition of hydrogens which 
any PDB file of the molecule usually does not contain, using the 
edit option in ADT. The ligands aspirin and cefazolin were 
separately and individually docked with HuPON1, grid for 
dock search was built for the whole molecule to find the most 
probable binding site in HuPON1 and to measure its interaction 
parameters with aspirin and cefazolin. The docking process was 
carried out in the default parameters of ADT. Binding sites has 
been predicted by submitting the model to 3D2GO binding site 
prediction server (http://www.sbg.bio.ic.ac.uk).  
 
 
Figure 1: (a) Sequence alignment of HuPON1 with rePON1 
(PDB: IV04). Strictly conserved residues are highlighted in red 
and partially conserved residues in white boxes. (b) Theoretical 
model of HuPON1 predicted using homology modelling. (c) 
Superimposition of HuPON1 (colored in green) with rePON1 
(colored in red). 
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Results and Discussion: 
Structural evaluation: 
Present study reports the structural interaction between 
HuPON1 with one inhibitor and one activator separately. 
rePON1 (PDB ID: 1V04) having high degree of homology with 
HuPON1 was used as a template with identity of 83% with 
atomic resolution of its x-ray crystal structure at 2.2 Å and R 
value being 0.189.  The secondary structure alignment obtained 
between the query and template sequence is shown in Figure 
1a. The query (HuPON1) subjected for homology modeling by 
Modeller ended up with a loop by default modeling process. 
Then, it was submitted to 
http://modbase.compbio.ucsf.edu/modloop/ server to rebuild 
into secondary structure, where loop attained alpha helix 
conformation (Figure 1b). Root mean square deviation (RMSD) 
value between the template and predicted loop model was 
f o u n d  t o  b e  0 . 2 0 2 ,  i n d i c a t i v e  o f  a  g o o d  m o d e l.  T h e  G - f a c to r s  
indicating the quality of covalent and bond angle distance were 
-0.09 for dihedrals, -0.32 for covalent, and overall -0.14. The 
predicted model was subjected to PROCHECK analysis to 
determine psi and phi torsion angles, the comparable 
Ramachandran plot characteristics and G-factors confirm the 
quality of predicted model (Table 1, see Supplementary 
material).  
 
The overall topology of modeled structure is a β propeller 
consisting of five alpha helices with multiple beta folds. Top 
view of PON1 appears to be a 6 bladed β propeller; each blade 
is composed of four β strands. The residues comprising the β-
sheets of the propeller were highly conserved among all PON 
sequences, while the majority of the variation among the 
paralogs was located primarily in the 3 helices forming a 
unique lid over the active site of PON1. The crystal structure of 
the rePON1 also revealed a six bladed β-propeller protein 
centrally arranged around two calcium ions (PDB: 1V04), which 
is similar to the DFPase-based homology model [16, 17]. The N-
terminal sequence (helix1) is the main determinant for PON’s 
cell distribution, translocation and secretion; both Helix H1 and 
H2 provide hydrophobic anchors for binding to the HDL 
particle and retain its hydrophobic N terminus which resembles 
a signal peptide. It is believed that PON1 anchors to HDL 
through this peptide and the other helices are also likely to have 
a profound effect on their protein-lipid and protein-protein 
interactions [18]. HuPON1 is always found in association with 
ApoA1 of HDL suggesting strong protein-protein interaction. 
Insights into the 3D structure and mechanistic studies also 
enabled a detailed description of PON1 active site. PON1 has 
two calcium atoms, one of which probably has catalytic and the 
other has structural role. These are 7.4 Å apart and are located 
in the central tunnel of the β propeller. The catalytic calcium is 
within 2.2-2.5 Å from oxygens of N224, N270, N68, D269 and 
E53 [16]. HuPON1 is considered to be a complex in substrate 
recognition and catalytic reactions mediated through multiple 
mechanisms and residues. Substantial efforts have focused on 
identifying amino acid residues important for HuPON1 
enzymatic activity and have revealed that the residues affecting 
the diverse activities of HuPON1 (lactonase/esterase and 
phosphotriesterase) are located in different regions of the active 
site [19]. The enzymatic catalysis of various substrates by PON1 
is known to be mediated by a unique H115–H134 dyad, which 
deprotonates a water molecule to generate the attacking 
hydroxide ion and accounts for the hydrolytic activity of PON1 
[9, 20].  Kinetic and site-directed mutagenesis studies have been 
extensively investigated to delineate substrate specificity and 
identified number of residues important for esterase and PON1 
activities, These residues include L69, H115, H134, D169, F222, 
D269, H285, F292, T332, V346 and W281, and substitution of 
these residues results in diminution or loss of function [21]. A 
disulphide bridge formed between C42 and C353 stabilizes the 
3D structure. Moreover, eight amino acids have been identified 
as essential for PON1 activities, which are W280, H114, H133, 
H154, H242, H284, E52 and D53 [16]. Sequence variation 
between HuPON1 and rePON1 found in regions that do not 
affect their active sites. Since HuPon1 has been modeled after 
the template (PDB: 1V04), it is likely that these interactions 
which are predicted may also hold good for the HuPON1-HDL 




Figure 2: Receptor-ligand interaction between cefazolin and 
modeled HuPON1 enzyme obtained using Autodock 4.0; (a) 
Active site of HuPON1 with cefazolin; (b) Electrostatic surface 
of HuPON1 binding pocket and interacting residues for 
cefazolin drug. 
 
Docking study and binding site prediction: 
Docking was performed using AUTODOCK 4.0 for the receptor 
of PON1 with ligands aspirin and cefazolin, loaded 
individually into ADT to analyze ten best conformations. The 
study showed that the conformation of cefazolin with PON1 
has binding energy of -5.5k.cal M-1 and binding 
constant/inhibitory constant of 80.71µM. While, the 
conformation of aspirin had lower binding energy than that of BIOINFORMATION  open access 
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cefazolin (-4.85k.cal M-1) and higher binding 
constant/inhibitory constant (276.3µM). The ligand binding 
residues of cefazolin and aspirin showed similarity with 
binding site predicted in our model and those predicted by the 
3D2GO (Table 2, see Supplementary material). Cefazolin was 
found to dock in the vicinity of predicted binding site 1 of 
HuPON1 (Figure 2a) and restored all its H-bond contacts with 
predicted site residue by residue with slight variations from 
3D2GO. However, aspirin was found to dock in vicinity of the 
predicted binding site 2 of HuPON1 (Figure 3a) and restored 
the geometrical premises of the predicted binding site but not 
the residues (Table 3, see Supplementary material). Cefazolin 
shares three hydrogen bonds and aspirin shares four hydrogen 
bonds with HuPON1. Furthermore, cefazolin docks at residues 
N166, S193 and Y71 (Figure 2b) and aspirin at residues N309, 
I310 and L311 (Figure 3b). 
 
 
Figure 3: Receptor-ligand interaction between aspirin and 
modeled HuPON1 enzyme obtained using Autodock 4.0; (a) 
Active site of HuPON1 with aspirin; (b) Electrostatic surface of 




In conclusion, model building and docking study were used to 
attain details of interaction between protein and ligands-aspirin 
and cefazolin. Docking studies of aspirin and cefazolin into the 
active site of HuPON1 revealed two binding sites; the first 
region is occupied by cefazolin and the second with aspirin. The 
multiple binding sites may possibly explain the multifunctional 
nature of HuPON1 towards structurally unrelated substrates. 
Furthermore, site directed mutagenesis has identified distinct 
amino acids for PON1 and phenyl acetate binding which are 
distinct from the residues important for binding aspirin and 
cefazolin. Therefore, screening many more substrates and 
inhibitors might provide the answers to the multi-factorial 
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Table 1: Validation statistics for theoretical model of PON1 by procheck analysis 
Plot statistics 
Residues in most favored regions   275  89.0% 
Residues in additional allowed regions  30  9.7% 
Residues in most generously allowed regions  3  1.0% 
Residues in disallowed regions  1  0.3% 
Number of non-glycine and non-proline 
residues 
309 100.0% 
 Number of end –residues (excl. Gly and Pro)  2   
Number of glycine residues   24   
Number of proline residues  20   
Total number of residues  355   
  
Table 2: Predicted binding sites of PON1 by 3DGO server (http://www.sbg.bio.ic.ac.uk/phyre/pfd/) 
Binding site  Residues 
Site 1  N224, D269, N168, F222, L240, D183 
Site 2  I228, S229, N227, P230, A172, G232 
 
Table 3: Residues interacting in binding sites of PON1 with cefazolin and aspirin 
Molecule  Amino acid residues involved 
in binding pocket of model 







        LIG: N-HD22 
        LIG: S-HG 
        LIG: N-HH 
 2.1Å  
 2.2 Å 






        LIG: C:O-HN  
        LIG: C:0-HD22 
        LIG: C:0-NH 
        LIG: C:0- NH 
2.1 Å 
1.8 Å 
2.0 Å 
2.2 Å 
 